Pfizer Inc. (PFE)'s Breakthrough Vaccine Could Be A Victim Of Its Own Success
3/14/2014 8:30:35 AM
Yesterday morning at a conference on infectious disease in Hyderabad, India, Marc Bonten, an epidemiologist from Utrecht University, the Netherlands, presented results from a giant and innovative study Pfizer conducted of its vaccine, Prevnar 13, in adults over 65. In 84,496 Dutch patients over the age of 65, those who got a Prevnar 13 shot were 45.6% less likely to get serious pneumonia caused by the bacteria strains covered by Prevnar 13 than those who received a placebo shot. “Now, for the first time we know that a vaccine can prevent pneumonia in the elderly,” Bonten told me via phone.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by